Pfizer 利益(をあげる)s ロケット/急騰する by 61% to $7.86B as 歳入 swells 77% 予定 to Covid ワクチン and Paxlovid pill - but 在庫/株 slips as it fails to raise 十分な-year sales 予測(する)

  • Pfizer on Tuesday 地位,任命するd 逮捕する income of $7.86 billion, up 61% from last year
  • COVID-19 ワクチン Comirnatybrought in $13 billion in sales in the 4半期/4分の1
  • Pill 治療 Paxlovid, which 開始する,打ち上げるd late last year, 追加するd another $1.5 billion?

COVID-19 ワクチン and 治療 sales helped Pfizer 微風 past 塀で囲む Street's first-4半期/4分の1 期待s, as the drugmaker's 利益(をあげる) grew 61 パーセント.

The coronavirus ワクチン Comirnaty, which has been Pfizer's 最高の,を越す 販売人 for about a year, brought in more than $13 billion in sales in the 4半期/4分の1. The pill 治療 Paxlovid, which 開始する,打ち上げるd late last year, 追加するd another $1.5 billion.

All that helped company 歳入 swell 77 パーセント, compared to last year's 4半期/4分の1, when ワクチン sales were still ramping up.

But in a 調印する that the days of dizzying growth are coming to an end, Pfizer didn't 引き上げ(る) its 十分な-year sales 予測(する) for both 製品s, 同様に as total 歳入, and company 株 slipped in 早期に 貿易(する)ing before erasing earlier losses.

全体にわたる, Pfizer on Tuesday 地位,任命するd 逮捕する income of $7.86 billion, and adjusted 収入s of $1.62 per 株 in the first 4半期/4分の1, easily topping the $1.49 事業/計画(する)d by 産業 分析家s, によれば a 調査する by FactSet.

歳入 was $25.66 billion, also (警官の)巡回区域,受持ち区域ing 塀で囲む Street 期待s for $24.1 billion.

Pfizer CEO Albert Bourla is seen in a file photo.
 Pfizer breezed past Wall Street's first-quarter expectations, as the drugmaker's profit grew 61 percent

Pfizer CEO Albert Bourla is seen in a とじ込み/提出する photo. Pfizer 微風d past 塀で囲む Street's first-4半期/4分の1 期待s, as the drugmaker's 利益(をあげる) grew 61 パーセント

Pfizer shares?slipped in early trading before turning positive as the market digested the report

Pfizer 株?slipped in 早期に 貿易(する)ing before turning 肯定的な as the market digested the 報告(する)/憶測

The company's 不本意 to 解除する its 予測(する) for Paxlovid could 示唆する a dearth of new sales 契約s for the pill during the first 4半期/4分の1.

In 用意が出来ている 発言/述べるs for the company's 会議/協議会 call with 投資家s, CEO Albert Bourla said the company had seen a 重要な 好転 in the 麻薬's use in the 部隊d 明言する/公表するs recently, and that some countries experiencing 最近の 突発/発生s had asked for more 治療 courses.

'We 推定する/予想する the 最近の 傾向s to 拡大する 接近, 同様に as 調査s received from 政府s as the ウイルス 突然変異するs and 原因(となる)s spikes in 感染s around the world, to result in 増加するd orders in the coming months,' Bourla sai d.

Bourla received $24.3 million in total 補償(金) for 2021, a 15 パーセント 増加する over the 事前の year.?

In Tuesday's 収入s 報告(する)/憶測, Pfizer also 繰り返し言うd its 予測(する) of $32 billion in sales from the ワクチン it developed with BioNTech.?

It had 以前 raised the 予測(する) for the ワクチン's sales every 4半期/4分の1 in 2021.

The pill treatment Paxlovid, which launched late last year, added $1.5 billion in sales

The pill 治療 Paxlovid, which 開始する,打ち上げるd late last year, 追加するd $1.5 billion in sales?

Pfizer's COVID-19 ワクチン 開始する,打ち上げるd in late 2020 and became the drugmaker´s 最高の,を越す selling 製品 by last year´s second 4半期/4分の1. That was before children started receiving the 予防の 発射s and adults began receiving booster doses.

Pfizer 調書をとる/予約するs the 広大な 大多数 of 歳入 from Comirnaty and 分裂(する)s 利益(をあげる), 同様に as the cost to make and 分配する the ワクチン, with 開発 partner BioNTech.

Sales of that ワクチン topped a nalyst 期待s for the 4半期/4分の1, but 歳入 from Paxlovid fell short.

Pfizer said it still 推定する/予想するs Comirnaty to bring in about $32 billion in sales this year, with Paxlovid 記録,記録的な/記録するing around $22 billion.

歳入 from both 製品s will likely 勝利,勝つd up 越えるing 予測(する)s, Mizuho 安全s USA 分析家 Dr. Vamil Divan said in a 研究 公式文書,認める. He 公式文書,認めるd that 現在の 発射/推定s only 含む 契約s the company 調印するd as of 中央の April.

Outside Comirnaty and Paxlovid, Pfizer makes several 癌 治療s, other ワクチンs and 内部の 薬/医学 麻薬s like Eliquis, for 妨げるing 血 clots and 一打/打撃s.

Sales of that 麻薬 climbed 12 パーセント 除外するing the 衝撃 of foreign 通貨 率s, to $1.79 billion in the 4半期/4分の1.

Pfizer's COVID-19 vaccine launched in late 2020 and became the drugmaker´s top selling product by last year´s second quarter

Pfizer's COVID-19 ワクチン 開始する,打ち上げるd in late 2020 and became the drugmaker´s 最高の,を越す selling 製品 by last year´s second 4半期/4分の1

Pfizer stock reacted sluggishly to the latest earnings

Pfizer 在庫/株 反応するd sluggishly to the 最新の 収入s?

Pfizer Inc., based in New York, also 改訂するd the 2022 収入s 予測(する) it debuted in February to 反映する an accounting 政策 change. It now 推定する/予想するs adjusted 収入s of $6.25 to $6.45 per 株.

That's 負かす/撃墜する a 薄暗い on both ends of the 範囲 from its previous 予測(する) for $6.35 to $6.55 per 株.

分析家s 予測(する) 収入s of $7.14 per 株.

The company still 推定する/予想するs that 2022 total 歳入 will 範囲 between $98 billion and $102 billion. 分析家s 予測(する) total 歳入 of $105.92 billion.

株 slipped 32 cents to $48.02 before the 開始 bell Tuesday.

Pfizer´s 在庫/株 攻撃する,衝突する an 史上最高 price of $61.71 on Dec. 20. But that price has fallen 18% so far this year, a steeper 減少(する) than the 概略で 13% 拒絶する/低下する of the 基準 & Poor´s 500 索引.

The comments below have not been 穏健なd.

The 見解(をとる)s 表明するd in the contents above are those of our 使用者s and do not やむを得ず 反映する the 見解(をとる)s of MailOnline.

By 地位,任命するing your comment you agree to our house 支配するs.